BRCA1 and BRCA2 genetic testing in women with epithelial ovarian cancer

When you first hear the words “epithelial ovarian cancer,” your brain understandably stops at
the word cancer. The last thing you probably want to think about is genetics homework.
But BRCA1 and BRCA2 genetic testing isn’t just a science projectit can shape your treatment
options today and help protect your family tomorrow.

In recent years, expert groups have moved from a “maybe” to a very clear “yes, please” on
genetic testing for women diagnosed with epithelial ovarian cancer. Instead of only testing
women who look high risk based on family history, major guidelines now recommend offering
BRCA1 and BRCA2 testing to all women with epithelial ovarian cancer, regardless of
age or family history. That shift is a big deal for treatment, survival, and prevention in
families.

In this in-depth guide, we’ll walk through why BRCA1 and BRCA2 matter, who should be tested,
what the test can (and cannot) tell you, and how results affect treatment and family planning.
We’ll also talk about real-world experiencesbecause in the clinic, decisions rarely feel as
simple as flow charts make them look.

Why BRCA1 and BRCA2 matter in epithelial ovarian cancer

BRCA1 and BRCA2 are tumor suppressor genesthink of them as high-end DNA repair crews that fix
damage before it turns into cancer. When one of these genes has a harmful inherited change
(called a pathogenic variant or mutation), DNA mistakes can pile up, increasing the risk of
certain cancers, especially breast and ovarian cancer.

For women with a BRCA1 or BRCA2 mutation, lifetime risks are dramatically higher than in the
general population. Large studies suggest that by age 80, about
44% of BRCA1 carriers and around 17% of BRCA2 carriers will develop ovarian
cancer, compared with roughly 1–2% in the general population. Breast cancer risk can climb to
around 70% or more in both BRCA1 and BRCA2 carriers by age 80. Those are not small bumps; they
are completely different risk categories.

Importantly, BRCA1/2-related ovarian cancers are usually the common epithelial typesespecially
high-grade serous carcinoma. That’s exactly the group we’re talking about in this article:
women already diagnosed with epithelial ovarian cancer who are deciding whether to pursue
genetic testing.

Who should be offered BRCA1 and BRCA2 genetic testing?

Short answer: all women with epithelial ovarian cancer should be offered germline BRCA
testing, regardless of age, stage, or family history.

Major professional organizations, including the American Society of Clinical Oncology (ASCO) and
the National Comprehensive Cancer Network (NCCN), now recommend that every woman with epithelial
ovarian, fallopian tube, or primary peritoneal cancer be offered testing for BRCA1, BRCA2, and
other hereditary ovarian cancer genes. This “universal testing” approach is based on a few key
realities:

• Around 15–20% of women with epithelial ovarian cancer carry an inherited mutation in
  BRCA1 or BRCA2.
• Many of these women do not have a strong family history that would have raised red
  flags in the past.
• Knowing BRCA status can change treatment decisions today, not just future screening.

In other words, relying on age and family history alone means you miss a lot of people who
could benefit from targeted therapies and preventive steps for their relatives. Universal
testing aims to close that gap.

Germline vs. somatic testing: what’s the difference?

BRCA testing in ovarian cancer actually comes in two flavors, and they answer slightly
different questions.

Germline BRCA1/BRCA2 testing

Germline testing looks for inherited BRCA1 and BRCA2 mutations in your normal DNAusually from
a blood draw or saliva sample. If a germline mutation is found, it means the mutation is
present in all of your cells and can be passed on to children. It also means that biological
relatives may carry the same mutation.

Key reasons germline testing matters include:

• It identifies hereditary cancer risk for you and your family members.
• It may make you eligible for targeted treatments like PARP inhibitors.
• It helps guide preventive measures (such as risk-reducing surgery or enhanced screening) for
  relatives who test positive.

Somatic (tumor) BRCA testing

Somatic testing analyzes DNA directly from the tumor itself. Tumor cells often acquire extra
mutations as they grow. Sometimes, a BRCA1 or BRCA2 mutation is present only in the tumor
(somatic) and not inherited in the rest of the body.

Why do oncologists care? Because both germline and somatic BRCA mutations can make tumors more
sensitive to drugs like PARP inhibitors, which exploit the tumor’s DNA repair weakness.

Many guidelines now suggest a two-step strategy:

1. First, do germline testing. If no inherited mutation is found…
2. Then consider tumor testing to look for somatic BRCA mutations or other
   “HRD” (homologous recombination deficiency) changes that might still predict benefit from
   targeted therapies.

How BRCA1/BRCA2 genetic testing shapes treatment

Genetic testing isn’t just academic. A confirmed BRCA1 or BRCA2 mutation can open doors to
specific treatment strategies:

PARP inhibitors and maintenance therapy

For many women with advanced epithelial ovarian cancer who respond to platinum-based
chemotherapy, PARP inhibitors (such as olaparib, niraparib, and others) have become key players
in maintenance therapy. Tumors with BRCA mutations struggle to repair certain types of DNA
damage, and PARP inhibitors take advantage of that vulnerability.

Clinical trials show that women with BRCA-mutated tumorsespecially those with germline BRCA1
or BRCA2 mutationsoften have longer periods before the cancer comes back when treated with a
PARP inhibitor after chemotherapy. In plain language: the treatment can help keep the cancer
quiet for longer.

Clinical trials and emerging therapies

BRCA status is now a common eligibility criterion for ovarian cancer clinical trials testing
new combinations of targeted therapies, immunotherapy, and novel agents. Knowing your genetic
status early in your treatment journey can expand your options if you and your oncologist want
to consider trials now or in the future.

Surgical and preventive decisions

For women diagnosed at a younger age or with early-stage disease, BRCA test results can also
influence decisions about:

• Risk-reducing removal of the remaining ovary or fallopian tube tissues.
• Future breast cancer risk management, including enhanced screening or prophylactic surgery.
• Timing of family planning or fertility preservation, when relevant.

These are deeply personal decisions, but genetics provides a more precise risk map to guide
them.

What BRCA test results can show

Genetic testing isn’t just “positive” or “negative.” There are a few common categories of
results, each with different implications.

Pathogenic or likely pathogenic variant

This is the classic “positive” result. It means there is a harmful change in BRCA1 or BRCA2
that clearly increases cancer risk and can be inherited. For women with ovarian cancer, this
result:

• Confirms a diagnosis of hereditary breast and ovarian cancer syndrome (HBOC).
• Supports use of PARP inhibitors or other targeted treatments, when appropriate.
• Triggers a recommendation for “cascade” testing of close relatives.

Negative result

A negative result means no clearly harmful BRCA1 or BRCA2 mutation was found. That does not
erase the ovarian cancer diagnosis, and it doesn’t mean risk is zero for relatives. However, it
makes an inherited BRCA-related syndrome less likely.

Sometimes, a negative BRCA result leads clinicians to consider a broader multigene panel for
other ovarian cancer susceptibility genes. Or, if the tumor has suspicious features, somatic
testing may still be recommended for treatment planning.

Variant of uncertain significance (VUS)

A VUS is the genetic equivalent of “we found something, but we’re not sure what it means yet.”
It’s a DNA change that isn’t clearly normal, but also isn’t clearly harmful. This can be
frustrating for patients, but there are a few key points:

• A VUS should not be treated as a positive mutation.
• Management usually relies on your personal and family history, not the VUS alone.
• Over time, as more data accumulates, many VUS are reclassified as either benign or
  pathogenic. Your genetics team may update you if that happens.

Benefits for family members: cascade testing and prevention

One of the most powerful aspects of BRCA1 and BRCA2 testing is its ripple effect through a
family. When a woman with epithelial ovarian cancer is found to have an inherited BRCA
mutation, her close relativessiblings, children, and sometimes more distant relativescan be
offered targeted testing for that specific mutation.

If a relative tests positive, they can:

• Start enhanced breast screening earlier and more frequently.
• Discuss preventive options, like risk-reducing removal of ovaries and fallopian tubes at an
  appropriate age, which can substantially lower ovarian cancer risk.
• Make informed decisions about family planning.

If a relative tests negative for the known family mutation, that’s also powerful information:
they typically go back to the general population risk level rather than being treated as
high-risk for life.

Practical considerations: counseling, cost, and timing

The role of genetic counseling

Genetic counseling is the “translation service” between complex lab reports and real-life
decisions. A genetic counselor or genetics-trained provider:

• Explains what BRCA testing can and cannot tell you.
• Reviews your personal and family history.
• Helps you think through how results might affect treatment and relatives.
• Supports you emotionally as you process risk information.

Many centers offer “mainstreaming” models where oncologists order tests directly and involve
genetics specialists when results come back positive or uncertain. Others still rely on formal
pre-test counseling. Either way, you should have access to someone who can answer your
questions in plain language.

Insurance coverage and cost

In the United States, BRCA testing for women who already have ovarian cancer is often covered
by insurance, given the strong guideline support and impact on treatment. Coverage and out-of-
pocket costs vary, so it’s worth checking with your insurer and the testing lab. Many labs have
financial assistance programs or maximum out-of-pocket caps to keep testing affordable.

When during treatment should testing happen?

Ideally, genetic testing is done soon after diagnosis, so results are available when
you and your oncologist are making decisions about surgery, chemotherapy, and maintenance
therapy. That said, it’s never “too late” to testresults can still be helpful years after
treatment, both for your long-term care and for family members.

Common fears and myths about BRCA testing

Even when doctors recommend BRCA testing, many women hesitateand not because they don’t care.
Common worries include:

• “I already have cancer. Why does it matter?” It matters because it can change
  which medicines you’re eligible for and how aggressively your doctors monitor for other
  cancers in the future. It also matters for your relatives’ cancer prevention.
• “I don’t want my family to worry.” That’s understandable. But not knowing the
  risk doesn’t make it smaller; it just makes it less visible. Many relatives prefer having the
  option to test and take action, even if it’s scary.
• “I’m worried about privacy and discrimination.” In the U.S., federal laws like
  GINA (the Genetic Information Nondiscrimination Act) offer protections against genetic
  discrimination in health insurance and employment. These protections don’t cover every type of
  insurance (like life or long-term care), so it’s worth discussing details with your genetics
  provider before testing.

Bottom line: BRCA1 and BRCA2 genetic testing brings up emotional, financial, and ethical
questionsbut you don’t have to sort through them alone. Your oncology and genetics teams are
there to help.

Real-world experiences with BRCA testing in epithelial ovarian cancer

Guidelines are neat; human lives are not. To understand how BRCA testing really plays out, it’s
useful to look at common experiences from the perspectives of patients, families, and care
teams. While details differ from person to person, certain themes show up again and again.

From the patient’s perspective: information overload and delayed “aha” moments

Many women first hear about BRCA testing in the chaos of diagnosis week, somewhere between “You
need surgery,” “Let’s talk chemotherapy,” and “Here’s a stack of new specialist appointments.”
It’s not exactly the ideal headspace for calmly considering inherited cancer risk.

A typical story goes something like this: the oncologist mentions genetic testing at the first
or second visit. The patient nods politely, but emotionally she’s still stuck on “Do I need a
port?” and “Will I lose my hair?” The test order gets placed, blood is drawn, and results
arrive a few weeks laterright when she finally starts to come up for air after surgery or the
first chemo cycles.

That’s often when the genetic result suddenly feels real. For women who learn they carry a
BRCA1 or BRCA2 mutation, the news can hit on multiple levels:

• Relief that there is a clear explanation and a clear plan for targeted therapy.
• Guilt and worry about children or siblings who might also carry the mutation.
• A strange sense of validation“This wasn’t my fault; my DNA came preloaded with this risk.”

Over time, many women describe the information as empowering, even if it was initially
overwhelming. It gives them a language to talk about risk with family, a framework to decide on
preventive steps, and a concrete reason to consider certain treatments.

From the family’s perspective: the domino effect

When a woman with ovarian cancer tests positive for a BRCA mutation, relatives often go through
their own emotional rollercoaster. Some are eager to test immediatelythese are the
“knowledge-is-power” people. Others need time. A few would rather not know at all, worried that
a positive result will cast a permanent shadow over their lives.

In practice, families rarely move in perfect sync. One daughter might schedule testing the week
after her mother’s result; another may wait years. A cousin might quietly call a genetic
counselor on her own. Over time, however, many families find a new normal where talking about
BRCA status is just part of routine health talk, like cholesterol numbers or blood pressure.

The most powerful recurring theme from families is this: when relatives test negative for the
known family BRCA mutation, the sense of relief is enormous. They still need age-appropriate
screening, but they can step off the “hereditary cancer syndrome” treadmill. For those who do
test positive, at least the risk is no longer a lurking unknownit’s something they can plan
around.

From the care team’s perspective: closing the testing gap

On the clinical side, oncologists and genetics professionals see another pattern: despite clear
guidelines, not every woman with epithelial ovarian cancer actually receives BRCA testing.
Barriers include limited access to genetic counseling, busy clinics, confusion about who is
responsible for ordering tests, and patients feeling too overwhelmed to engage with genetics
during active treatment.

Many cancer centers have responded by building streamlined “mainstream” genetic pathways where
oncologists order tests directly at diagnosis, with automatic referrals to genetics only for
positive or complex results. Others embed genetic counselors in gynecologic oncology clinics so
patients can ask questions on the spot.

The goal is simple: if all women with epithelial ovarian cancer are supposed to be offered
genetic testing, systems should make the “right thing” the easy thing. When that happens, more
women get timely access to targeted therapies, and more families get the information they need
to lower their own cancer risk.

Living with a BRCA mutation after ovarian cancer

For women who survive epithelial ovarian cancer and carry a BRCA mutation, life after treatment
becomes a long-term balancing act. They juggle:

• Follow-up visits to monitor for recurrence.
• Decisions about breast cancer screening or surgery.
• Conversations with adult children about their own testing choices.
• Occasional waves of anxiety triggered by headlines about genetics and cancer.

Many women report that, over time, the BRCA label becomes less of a spotlight and more of a
guidebook. Yes, it changes some recommendations, but it also helps them feel they are doing
everything reasonably possible to stay ahead of future cancersor to help their children do so.

Ultimately, BRCA1 and BRCA2 genetic testing in women with epithelial ovarian cancer isn’t about
perfection or certainty. It’s about clearer information, better-matched treatments, and giving
families a chance to rewrite the story of cancer risk for the next generation.

Conclusion

BRCA1 and BRCA2 genetic testing has moved from a niche “maybe” for a few high-risk families to
a core part of care for all women diagnosed with epithelial ovarian cancer. The
reasons are compelling: test results can guide modern targeted therapies, inform surgical and
screening decisions, and provide life-changing information for relatives.

If you or someone you love is facing epithelial ovarian cancer, talking with your oncology team
and a genetic counselor about BRCA testing is a practical, powerful step. It won’t answer every
question, but it can turn some of the uncertainty into a clearer planfor today’s treatment and
tomorrow’s prevention.